Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 42kWORD 19k
19 July 2019
Question for written answer E-002328-19
to the Commission
Rule 138
João Ferreira (GUE/NGL)

 Subject:  EU and Member States' roles in tackling Alzheimer's
 Answer in writing 

According to recent news reports, the pharmaceutical giant Pfizer hid the discovery of a medical product that could prevent Alzheimer’s purely for financial reasons.

Yet evidence has come to light which proves that Enbrel — one of the most popular medicines for rheumatoid arthritis — works well against Alzheimer’s, reducing the risks by 65%. However, clinical trials are required to prove how effective Enbrel really is, and Pfizer is against this.

Given that Alzheimer’s is expected to affect around 56 million people by 2030, there is no doubt that drug development is absolutely crucial.

If multinational pharmaceutical companies are going to put profits before public interest, public authorities must find other ways of developing the pharmaceutical products that are needed.

1. What (public and private) projects is the EU supporting to tackle Alzheimer’s?2. Why has the Commission disbanded the Governmental Expert Group on Dementia, which was composed of Member States and members of the public?3. Does the Commission intend to encourage Member States to share expertise and best practices and to adopt national strategies to tackle Alzheimer’s?

Original language of question: PT 
Last updated: 5 August 2019Legal notice